Published in Gut on December 01, 1977
Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br Med J (1978) 1.31
Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection. Clin Exp Immunol (1987) 1.16
Anti-LSP antibodies in acute liver disease. Gut (1982) 1.05
Relationship between T cell subsets and suppressor cell activity in chronic hepatitis B virus (HBV) infection. Clin Exp Immunol (1983) 1.04
Cellular and humoral immune reactions in chronic active liver disease. II. Lymphocyte subsets and viral antigens in liver biopsies of patients with acute and chronic hepatitis B. Clin Exp Immunol (1984) 1.03
Functional characterization of peripheral blood lymphocytes in chronic HBsAg carriers. Clin Exp Immunol (1986) 0.89
Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses. Antimicrob Agents Chemother (1979) 0.83
Cellular cytotoxicity against autologous hepatocytes in acute and chronic non-A, non-B hepatitis. Gut (1984) 0.81
Delayed type hypersensitivity (DTH) skin reaction to hepatitis B surface antigen (HBsAg) in patients with type B acute and chronic hepatitis. Clin Exp Immunol (1985) 0.81
Influence of (+)-cyanidanol-3 on the leukocyte migration inhibition test carried out in the presence of purified protein derivative and hepatitis B surface antigen. Infect Immun (1981) 0.79
Lymphocyte cytotoxicity for autologous hepatocytes. Gut (1984) 0.77
Antibody dependent cellular cytotoxicity (ADCC) in acute hepatitis B and in chronic active hepatitis. Clin Exp Immunol (1978) 0.77
Immunisation against hepatitis B. Br Med J (1980) 0.75
Cytotoxic effects of lymphoid cells in vitro. Adv Immunol (1969) 8.18
Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet (1972) 5.17
Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma. Lancet (1972) 4.36
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Australia antigen: large-scale purification from human serum and biochemical studies of its proteins. J Virol (1971) 3.28
Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet (1976) 3.16
A new rapid method for genetic typing of human immunoglobulins. J Immunol (1968) 2.61
Cytoplasmic localisation of Australia antigen in the liver. Lancet (1972) 1.80
Lymphocyte stimulation in hepatitis B infections. N Engl J Med (1975) 1.60
Cellular and humoral immunity to hepatitis-B surface antigen in active chronic hepatitis. Br Med J (1975) 1.47
Liver cell surface localization of hepatitis B antigen and of immunoglobulins in acute and chronic hepatitis and in liver cirrhosis. Clin Exp Immunol (1976) 1.35
Lymphocyte transformation and leucocyte migration-inhibition by Australia antigen. Clin Exp Immunol (1973) 1.22
Cell-mediated immune reactivity to hepatitis B surface antigen in liver diseases. Gastroenterology (1975) 1.15
Immune responses to the hepatitis B surface antigen and liver-specific lipoprotein in acute type B hepatitis. Gut (1977) 1.08
A cytolytic system for the in vitro detection of cell-mediated immunity to soluble antigen. J Immunol (1970) 1.01
Cell-mediated immune response to hepatitis B antigen in patients with liver disease. Am J Dig Dis (1974) 0.99
[Presence of HBsAg and IgG on the membrane of hepatic cells in patients with acute and chronic hepatitis]. Minerva Gastroenterol (1977) 0.82
[Infection due to hepatitis B virus and host immune response]. Boll Ist Sieroter Milan (1976) 0.81
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med (1993) 4.36
A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology (1994) 4.01
HCV-associated liver cancer without cirrhosis. Lancet (1995) 3.23
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology (1993) 2.29
Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut (2004) 2.22
Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology (1980) 2.04
Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. J Immunol (1989) 2.00
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer (1994) 1.81
Natural history and prognostic factors for chronic hepatitis type B. Gut (1991) 1.75
Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature (1990) 1.74
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther (2011) 1.73
Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci (2000) 1.71
Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis (1991) 1.69
Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life. Dig Liver Dis (2005) 1.69
HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection. J Immunol (1989) 1.66
Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut (1982) 1.60
Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology (1989) 1.59
Incorrect echocardiographic diagnosis in patients with mechanical prosthetic valve dysfunction: correlation with surgical findings. Am J Med (2000) 1.55
Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat (2007) 1.54
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther (2011) 1.51
Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol (1992) 1.50
Mediterranean Adequacy Index: correlation with 25-year mortality from coronary heart disease in the Seven Countries Study. Nutr Metab Cardiovasc Dis (2004) 1.49
Nitric oxide pathway, Ca2+, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia (1999) 1.48
Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr (1999) 1.45
Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol (1994) 1.43
Dispersal flight by Triatoma infestans in an arid area of Argentina. Med Vet Entomol (1988) 1.43
Food habits in a southern Italian town (Nicotera) in 1960 and 1996: still a reference Italian Mediterranean diet? Diabetes Nutr Metab (2001) 1.41
ICHD 2nd Edition: Some considerations on the application of criteria for primary headache. Cephalalgia (2005) 1.41
Isolation of Helicobacter pylori from sheep-implications for transmission to humans. Am J Gastroenterol (2001) 1.40
Mees' lines due to cyclosporin. Br J Dermatol (1999) 1.39
Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother (1999) 1.38
Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology (1986) 1.38
[Coronary angioplasty in an Italian hospital without on-site cardiac surgery: the results and outlook]. G Ital Cardiol (1994) 1.38
Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology (1994) 1.37
Intracellular Mg++ concentration and electromyographical ischemic test in juvenile headache. Cephalalgia (1999) 1.37
Liver cell surface localization of hepatitis B antigen and of immunoglobulins in acute and chronic hepatitis and in liver cirrhosis. Clin Exp Immunol (1976) 1.35
Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia (2000) 1.32
Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br Med J (1978) 1.31
Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat (2006) 1.26
Differential distribution of hepatitis B core and E antigens in hepatocytes: analysis by monoclonal antibodies. Hepatology (1986) 1.26
Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology (1997) 1.24
Core antigen-specific immunoglobulin G bound to the liver cell membrane in chronic hepatitis B. Gastroenterology (1982) 1.24
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis (1987) 1.23
Suppressor cell activity in viral and non-viral chronic active hepatitis. Clin Exp Immunol (1980) 1.23
Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology (1988) 1.23
Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology (1990) 1.23
Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat (2007) 1.21
Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology (2000) 1.21
T lymphocyte sensitization to HBcAg and T cell-mediated unresponsiveness to HBsAg in hepatitis B virus-related chronic liver disease. Hepatology (1985) 1.20
Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut (1998) 1.20
The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol (1995) 1.19
Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Gut (2003) 1.17
Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology (1998) 1.17
Cloning and expression of a novel hepatitis B virus-binding protein from HepG2 cells. J Biol Chem (2001) 1.17
Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr (2001) 1.17
Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection. Clin Exp Immunol (1987) 1.16
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol (2000) 1.16
In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA. Hepatology (1995) 1.13
Patterns of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis and their relationship to viral replication and liver disease. Hepatology (1993) 1.13
Changes in hepatitis Be antigen/antibody system in children with chronic hepatitis B virus infection. J Pediatr (1983) 1.13
Ageing induces left ventricular concentric remodelling in normotensive subjects. J Hypertens (1995) 1.13
In vivo translational efficiency of different hepatitis C virus 5'-UTRs. FEBS Lett (1997) 1.12
High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology (1992) 1.12
Executive function in adolescents with Down Syndrome. J Intellect Disabil Res (2010) 1.12
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer (1998) 1.10
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1997) 1.09
Histological evidence of hepatitis-B-virus infection with negative serology in children with acute leukaemia who develop chronic liver disease. Lancet (1982) 1.09
Bone microarchitecture evaluated by histomorphometry. Micron (2005) 1.09
Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization. Transpl Int (1998) 1.09
Cellular immunity to the hepatitis B virion in acute hepatitis type B. Clin Exp Immunol (1983) 1.08
An antibody which precipitates Dane particles in acute hepatitis type B: relation to receptor sites which bind polymerized human serum albumin on virus particles. Hepatology (1984) 1.08
Letter: HBAg on liver-cell surface in viral hepatitis. Lancet (1975) 1.07